柏柏林衍生物的当前发展和结构-活性关系研究
Xiong-Fei Luo1, Han Zhou1, Peng Deng1
1School of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Bioorganic & medicinal chemistry
|August 31, 2024
概括
柏柏林是一种天然化合物,具有多种药理作用,如降低血糖和抵抗炎症. 结构修改增强了其特性,导致柏林衍生物的新疗法应用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
- 自然产品 自然产品
背景情况:
- 柏柏林是一种来自中国传统医药的天然异类素化物.
- 它具有广泛的药理作用,包括低血糖,低脂,抗瘤,抗微生物和抗炎作用.
- 柏柏林的结构修改可以改变其物理化学性质和生物活性.
研究的目的:
- 审查最近关于柏柏林的研究进展.
- 分析贝贝林衍生物的结构-活性关系.
- 为开发基于柏柏林的新疗法提供见解.
主要方法:
- 关于柏柏林及其衍生物的最新研究的文献综述.
- 基于已公布的数据,分析结构-活动关系.
- 合成和评估经过修改的柏柏林化合物 (隐含).
主要成果:
- 柏柏林具有显著的低血糖,低脂,抗瘤,抗微生物和抗炎作用.
- 结构修改可以优化柏柏林的疗效,并扩大其治疗潜力.
- 已经确定了各种药理学效应的关键结构-活性关系.
结论:
- 柏柏林是药物发现的有希望的支架.
- 有针对性的结构修改对于增强治疗效益至关重要.
- 进一步探索新的柏柏林衍生物具有显著的临床潜力.
相关概念视频
Structure-Activity Relationships and Drug Design
679
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
679
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.6K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.1K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.1K
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
903
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
903
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
543
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
543


